MedPath
Found 1 clinical trials|View Analysis
Sort by:

P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .

Phase 2
Withdrawn
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
Drug: Sabizabulin
Drug: Sabizabulin/Sacituzumab govitecan-hziy Combo
Drug: Sacituzumab Govitecan-hziy
First Posted Date
2021-08-17
Last Posted Date
2022-02-08
Lead Sponsor
Veru Inc.
Registration Number
NCT05008510
© Copyright 2025. All Rights Reserved by MedPath